Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

New Genetic Links to Colorectal Cancer Identified

January 3, 2013
By Anna Azvolinsky
Article

Using a large genome-wide study of more than 28,000 individuals, three new genetic links to colorectal cancer have been identified, holding the potential for new therapeutic targets.

Three new genetic links to colorectal cancer have been identified using a large genome-wide study of more than 28,000 individuals. The three new variants may hold potential new therapeutic targets and are helping researchers better understand the biology of colorectal cancer as well as the differential genetic basis of colorectal cancer in European and Asian populations. The study is published in Nature Genetics.

Researchers at the Vanderbilt-Ingram Cancer Center in Nashville, and colleagues in China, South Korea, and Japan analyzed 5,252 colorectal cancer cases and 9,071 control samples from the Asia Colorectal Cancer Consortium (ACCC) to identify novel colorectal cancer risk factors. The samples studied came from China, Japan, and Korea. The results were compared to the known genetic variants identified from European population results.

“This kind of work would not be possible without the support of investigators from multiple centers,” said Wei Zheng, MD, PhD, an Ingram professor of cancer research and lead author of the study.

The top four genetic loci were compared to two previous data sets-the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR). Three of these were within the previous data sets but there were not enough data for strong associations. The current study has found the “needles in a haystack,” said Zheng, by rigorously testing the results to identify true associations using the genome-wide association study data that can identify more than 25,000 variants, many of which are false positives.

“A lot of work has been done in European descendants,” said Zheng. “Our study is the first one conducted in multiple East Asian populations. Looking at different ethnic groups is important because the genetic structures can be different enough that variants identified in one population do not explain risk in other populations Sometimes-it is much easier to identify some genetic variants in East Asian populations than European descendants.”

One of the loci is in close proximity to the CCND2 gene, a cyclin that has a critical role in cell cycle progression and has been shown to be overexpressed in colorectal tumors in various studies including The Cancer Genome Atlas (TCGA). Another variant is located proximal to the PITXI gene, a tumor suppressor gene that may activate TP53 and regulate the activity of the enzyme telomerase, which adds telomeres to the ends of chromosomes. A third genetic variant includes two genes-HAO1, which encodes a hydroxyacid oxidase; and PLCB1, which encodes phospholipase C-β1. PLCB1 has been previously shown to be overexpressed in colorectal cancer tissue.

Further genetic analyses of colorectal cancer continue to be necessary. Previous genome-wide studies have isolated 15 common genetic susceptibility loci in colorectal cancer but only 15% of heritable colorectal cancer is explained by these loci. All but one of these colorectal cancer studies analyzed samples from European populations even though genetic variants from non-European populations differ from those of other populations, including Asian populations.

Moreover, only 6% of colorectal cancer cases are explained by the genetic variants previously identified and associated with a high risk of the disease.

In addition to its work on colorectal cancer, the team is working on breast cancer genetics to identify additional genetic loci that confer risk of developing cancer, leading a consortium that has identified multiple susceptibility loci for breast cancer in Asians. “Interestingly,” said Zheng, “these loci were not discovered in previous studies conducted in European descendants, even with a very large sample size.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

Russ Conroy
June 28th 2025
Article

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.


Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Related Content

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

Russ Conroy
June 28th 2025
Article

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.


Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.